IL140284A0 - Adenosine derivatives - Google Patents
Adenosine derivativesInfo
- Publication number
- IL140284A0 IL140284A0 IL14028499A IL14028499A IL140284A0 IL 140284 A0 IL140284 A0 IL 140284A0 IL 14028499 A IL14028499 A IL 14028499A IL 14028499 A IL14028499 A IL 14028499A IL 140284 A0 IL140284 A0 IL 140284A0
- Authority
- IL
- Israel
- Prior art keywords
- adenosine derivatives
- adenosine
- derivatives
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
- C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
- C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
- C07H19/16—Purine radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D473/00—Heterocyclic compounds containing purine ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
- A61K31/52—Purines, e.g. adenine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
- A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
- A61K31/7076—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/06—Antiarrhythmics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/08—Vasodilators for multiple indications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Biomedical Technology (AREA)
- Molecular Biology (AREA)
- Diabetes (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biochemistry (AREA)
- Pain & Pain Management (AREA)
- Genetics & Genomics (AREA)
- Biotechnology (AREA)
- Obesity (AREA)
- Epidemiology (AREA)
- Hematology (AREA)
- Vascular Medicine (AREA)
- Pulmonology (AREA)
- Rheumatology (AREA)
- Anesthesiology (AREA)
- Urology & Nephrology (AREA)
- Endocrinology (AREA)
- Emergency Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Saccharide Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB9813554.4A GB9813554D0 (en) | 1998-06-23 | 1998-06-23 | Chemical compounds |
| PCT/EP1999/004182 WO1999067262A1 (en) | 1998-06-23 | 1999-06-21 | Adenosine derivatives |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| IL140284A0 true IL140284A0 (en) | 2002-02-10 |
Family
ID=10834247
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IL14028499A IL140284A0 (en) | 1998-06-23 | 1999-06-21 | Adenosine derivatives |
| IL140284A IL140284A (en) | 1998-06-23 | 2000-12-13 | Adenosine derivatives |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IL140284A IL140284A (en) | 1998-06-23 | 2000-12-13 | Adenosine derivatives |
Country Status (40)
| Country | Link |
|---|---|
| US (2) | US6492348B1 (zh) |
| EP (2) | EP1090019B1 (zh) |
| JP (2) | JP3378240B2 (zh) |
| KR (1) | KR100612797B1 (zh) |
| CN (2) | CN1616459A (zh) |
| AP (1) | AP2000002014A0 (zh) |
| AR (1) | AR018917A1 (zh) |
| AT (1) | ATE277941T1 (zh) |
| AU (1) | AU758018B2 (zh) |
| BG (1) | BG65064B1 (zh) |
| BR (1) | BR9911498A (zh) |
| CA (1) | CA2335520C (zh) |
| CO (1) | CO5040216A1 (zh) |
| DE (1) | DE69920697T2 (zh) |
| EA (1) | EA003828B1 (zh) |
| EE (1) | EE04853B1 (zh) |
| ES (1) | ES2226399T3 (zh) |
| GB (1) | GB9813554D0 (zh) |
| GE (1) | GEP20032958B (zh) |
| HK (1) | HK1034978A1 (zh) |
| HR (1) | HRP20000896B1 (zh) |
| HU (1) | HUP0102453A3 (zh) |
| ID (1) | ID27484A (zh) |
| IL (2) | IL140284A0 (zh) |
| IS (1) | IS5773A (zh) |
| MY (1) | MY122481A (zh) |
| NO (1) | NO318788B1 (zh) |
| NZ (1) | NZ508915A (zh) |
| OA (1) | OA11574A (zh) |
| PE (1) | PE20000704A1 (zh) |
| PL (1) | PL194087B1 (zh) |
| PT (1) | PT1090019E (zh) |
| RS (1) | RS50042B (zh) |
| SI (1) | SI1090019T1 (zh) |
| SK (1) | SK19582000A3 (zh) |
| TR (1) | TR200100449T2 (zh) |
| TW (1) | TW541312B (zh) |
| UA (1) | UA64794C2 (zh) |
| WO (1) | WO1999067262A1 (zh) |
| ZA (1) | ZA200007514B (zh) |
Families Citing this family (33)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB9813554D0 (en) * | 1998-06-23 | 1998-08-19 | Glaxo Group Ltd | Chemical compounds |
| JP5042425B2 (ja) * | 2000-03-01 | 2012-10-03 | ユーロセルティック ソシエテ アノニム | 機能性胃腸疾患治療用トラマドール |
| US20040162422A1 (en) * | 2001-03-20 | 2004-08-19 | Adrian Hall | Chemical compounds |
| GB0106867D0 (en) | 2001-03-20 | 2001-05-09 | Glaxo Group Ltd | Process |
| GB0115178D0 (en) * | 2001-06-20 | 2001-08-15 | Glaxo Group Ltd | Compounds |
| GB0115182D0 (en) * | 2001-06-20 | 2001-08-15 | Glaxo Group Ltd | Medicaments |
| US6946449B2 (en) | 2001-07-13 | 2005-09-20 | Cv Therapeutics, Inc. | Partial and full agonists of A1 adenosine receptors |
| US7713946B2 (en) | 2002-07-11 | 2010-05-11 | Cv Therapeutics, Inc. | Partial and full agonists A1 adenosine receptors |
| US7157440B2 (en) | 2001-07-13 | 2007-01-02 | Cv Therapeutics, Inc. | Partial and full agonists of A1 adenosine receptors |
| JP2005527502A (ja) | 2002-02-19 | 2005-09-15 | シーブイ・セラピューティクス・インコーポレイテッド | Ａ１アデノシン受容体の部分的および全アゴニスト |
| EP1513858A2 (en) * | 2002-06-17 | 2005-03-16 | Glaxo Group Limited | Process for the preparation of heterocyclyl substituted adenosine derivatives |
| ATE368048T1 (de) * | 2002-08-15 | 2007-08-15 | Cv Therapeutics Inc | Partielle und volle agonisten von a1- adenosinrezeptoren |
| AU2003298204A1 (en) * | 2002-12-18 | 2004-07-09 | Glaxo Group Limited | Adenosine derivative in polymorph v form |
| AU2003290088A1 (en) * | 2002-12-18 | 2004-07-09 | Glaxo Group Limited | Adenosine derivative in polymorph iv form |
| AU2003292255A1 (en) * | 2002-12-18 | 2004-07-09 | Glaxo Group Limited | Polymorph |
| AU2004209986C1 (en) | 2003-02-03 | 2009-08-13 | Gilead Palo Alto, Inc. | Partial and full agonists of A1 adenosine receptors |
| WO2005053712A1 (en) * | 2003-12-02 | 2005-06-16 | Glaxo Group Limited | Use of adenonsine derivatives for treating dyslipidemia, obesity, cardiovascular risk factors, metabolic syndrome, polycystic ovary syndrome, niddm |
| GT200500281A (es) * | 2004-10-22 | 2006-04-24 | Novartis Ag | Compuestos organicos. |
| GB0500785D0 (en) * | 2005-01-14 | 2005-02-23 | Novartis Ag | Organic compounds |
| GB0607944D0 (en) * | 2006-04-21 | 2006-05-31 | Novartis Ag | Organic compounds |
| AR060607A1 (es) | 2006-04-21 | 2008-07-02 | Novartis Ag | Derivados de purina,composiciones farmaceuticas que los contienen, metodo de preparacion y usos en enfermedades obstructivas o inflamatorias de las vias respiratorias. |
| GB0607950D0 (en) * | 2006-04-21 | 2006-05-31 | Novartis Ag | Organic compounds |
| GB0607953D0 (en) * | 2006-04-21 | 2006-05-31 | Novartis Ag | Organic compounds |
| GB0607954D0 (en) * | 2006-04-21 | 2006-05-31 | Novartis Ag | Organic compounds |
| GB0607948D0 (en) * | 2006-04-21 | 2006-05-31 | Novartis Ag | Organic compounds |
| EP1889846A1 (en) | 2006-07-13 | 2008-02-20 | Novartis AG | Purine derivatives as A2a agonists |
| EP1903044A1 (en) * | 2006-09-14 | 2008-03-26 | Novartis AG | Adenosine Derivatives as A2A Receptor Agonists |
| MX2009004991A (es) * | 2006-11-10 | 2009-05-20 | Novartis Ag | Derivados de monoacetato de ciclopenteno-diol. |
| US20090088403A1 (en) * | 2007-05-07 | 2009-04-02 | Randy Blakely | A3 adenosine receptors as targets for the modulation of central serotonergic signaling |
| CN101712709A (zh) * | 2008-10-06 | 2010-05-26 | 中国医学科学院药物研究所 | 三乙酰基-3-羟基苯基腺苷及其调血脂的用途 |
| EP2849566B1 (en) * | 2012-02-11 | 2018-04-04 | Academia Sinica | Adenosine analogues for the treatment of pain |
| MX2017010844A (es) * | 2015-02-24 | 2017-12-07 | Pfizer | Derivados de nucleosidos sustituidos utiles como agentes anticancerosos. |
| CN108864099A (zh) * | 2018-09-08 | 2018-11-23 | 湖北荆洪生物科技股份有限公司 | 一种高纯6-糠氨基嘌呤的合成方法 |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4962194A (en) * | 1987-04-02 | 1990-10-09 | Warner-Lambert Company | Method of preparing 51,N6-disubstituted adenosines from inosines |
| US5646128A (en) * | 1989-09-15 | 1997-07-08 | Gensia, Inc. | Methods for treating adenosine kinase related conditions |
| US5244896A (en) * | 1990-09-14 | 1993-09-14 | Marion Merrell Dow Inc. | Carbocyclic adenosine analogs useful as immunosuppressants |
| DK62592D0 (zh) * | 1992-05-14 | 1992-05-14 | Novo Nordisk As | |
| GB9301000D0 (en) * | 1993-01-20 | 1993-03-10 | Glaxo Group Ltd | Chemical compounds |
| ES2132419T3 (es) * | 1993-07-23 | 1999-08-16 | Merrell Pharma Inc | Nuevos agentes de nucleosidos 9-n-biciclicos utiles como inhibidores selectivos de citocinas proinflamatorias. |
| WO1998001459A1 (en) * | 1996-07-05 | 1998-01-15 | Novo Nordisk A/S | Novel n-alkoxyadenine derivatives acting as cytokine inhibitors |
| UA51716C2 (uk) * | 1996-07-08 | 2002-12-16 | Авентіс Фармасьютікалз Продактс Інк. | Сполуки, що мають гіпотензивну, кардіопротекторну, анти-ішемічну та антиліполітичну властивості, фармацевтична композиція та способи лікування |
| AU4377397A (en) * | 1996-10-14 | 1998-05-11 | Novo Nordisk A/S | Novel therapeutically active adenosine derivatives |
| TW528755B (en) * | 1996-12-24 | 2003-04-21 | Glaxo Group Ltd | 2-(purin-9-yl)-tetrahydrofuran-3,4-diol derivatives |
| YU44900A (sh) | 1998-01-31 | 2003-01-31 | Glaxo Group Limited | Derivati 2-(purin-9-il)tetrahidrofuran-3,4-diola |
| PE20000270A1 (es) | 1998-02-14 | 2000-05-20 | Glaxo Group Ltd | Derivados de 2-(purin-9-il)-tetrahidrofuran-3,4-diol |
| GB9813554D0 (en) * | 1998-06-23 | 1998-08-19 | Glaxo Group Ltd | Chemical compounds |
-
1998
- 1998-06-23 GB GBGB9813554.4A patent/GB9813554D0/en not_active Ceased
-
1999
- 1999-06-21 TR TR2001/00449T patent/TR200100449T2/xx unknown
- 1999-06-21 CN CNA2004100119394A patent/CN1616459A/zh active Pending
- 1999-06-21 WO PCT/EP1999/004182 patent/WO1999067262A1/en active IP Right Grant
- 1999-06-21 EP EP99927999A patent/EP1090019B1/en not_active Expired - Lifetime
- 1999-06-21 OA OA1200000352A patent/OA11574A/en unknown
- 1999-06-21 DE DE69920697T patent/DE69920697T2/de not_active Expired - Lifetime
- 1999-06-21 PT PT99927999T patent/PT1090019E/pt unknown
- 1999-06-21 SI SI9930674T patent/SI1090019T1/xx unknown
- 1999-06-21 SK SK1958-2000A patent/SK19582000A3/sk unknown
- 1999-06-21 PL PL99345089A patent/PL194087B1/pl unknown
- 1999-06-21 NZ NZ508915A patent/NZ508915A/en unknown
- 1999-06-21 CN CNB998098957A patent/CN1202118C/zh not_active Expired - Fee Related
- 1999-06-21 ID IDW20010186A patent/ID27484A/id unknown
- 1999-06-21 MY MYPI99002543A patent/MY122481A/en unknown
- 1999-06-21 IL IL14028499A patent/IL140284A0/xx active IP Right Grant
- 1999-06-21 GE GEAP19995692A patent/GEP20032958B/en unknown
- 1999-06-21 EE EEP200000784A patent/EE04853B1/xx not_active IP Right Cessation
- 1999-06-21 HU HU0102453A patent/HUP0102453A3/hu unknown
- 1999-06-21 AP APAP/P/2000/002014A patent/AP2000002014A0/en unknown
- 1999-06-21 CA CA002335520A patent/CA2335520C/en not_active Expired - Fee Related
- 1999-06-21 BR BR9911498-4A patent/BR9911498A/pt not_active Application Discontinuation
- 1999-06-21 ES ES99927999T patent/ES2226399T3/es not_active Expired - Lifetime
- 1999-06-21 PE PE1999000547A patent/PE20000704A1/es not_active Application Discontinuation
- 1999-06-21 CO CO99038539A patent/CO5040216A1/es unknown
- 1999-06-21 KR KR1020007014749A patent/KR100612797B1/ko not_active IP Right Cessation
- 1999-06-21 US US09/736,018 patent/US6492348B1/en not_active Expired - Lifetime
- 1999-06-21 AT AT99927999T patent/ATE277941T1/de not_active IP Right Cessation
- 1999-06-21 RS YUP-828/00A patent/RS50042B/sr unknown
- 1999-06-21 AU AU45146/99A patent/AU758018B2/en not_active Ceased
- 1999-06-21 EA EA200001222A patent/EA003828B1/ru not_active IP Right Cessation
- 1999-06-21 JP JP2000555913A patent/JP3378240B2/ja not_active Expired - Lifetime
- 1999-06-21 EP EP04076465A patent/EP1447407A1/en not_active Withdrawn
- 1999-06-21 UA UA2000127404A patent/UA64794C2/uk unknown
- 1999-06-22 AR ARP990102993A patent/AR018917A1/es unknown
- 1999-07-01 TW TW088111178A patent/TW541312B/zh not_active IP Right Cessation
-
2000
- 2000-12-13 IL IL140284A patent/IL140284A/en not_active IP Right Cessation
- 2000-12-14 ZA ZA200007514A patent/ZA200007514B/en unknown
- 2000-12-15 IS IS5773A patent/IS5773A/is unknown
- 2000-12-20 NO NO20006520A patent/NO318788B1/no unknown
- 2000-12-21 HR HR20000896A patent/HRP20000896B1/xx not_active IP Right Cessation
-
2001
- 2001-01-15 BG BG105155A patent/BG65064B1/bg unknown
- 2001-08-14 HK HK01105686A patent/HK1034978A1/xx not_active IP Right Cessation
-
2002
- 2002-06-11 JP JP2002170486A patent/JP2003040891A/ja active Pending
- 2002-08-13 US US10/217,107 patent/US6677316B2/en not_active Expired - Lifetime
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PL345089A1 (en) | Adenosine derivatives | |
| PL346155A1 (en) | 1h-imidazopyridine derivatives | |
| PL345540A1 (en) | Thiobenzimidazole derivatives | |
| HU9900120D0 (en) | Benzosulfone derivatives | |
| GB9924361D0 (en) | Purine derivatives | |
| HUP0203419A3 (en) | Purine derivatives | |
| GB9924363D0 (en) | Purine derivatives | |
| PL347139A1 (en) | Imidazolyl derivatives | |
| GB9809664D0 (en) | a-Ketoamide derivatives | |
| EG23802A (en) | 2-Phenylpyran-4-one derivatives | |
| GB9827729D0 (en) | Thieno-indole derivatives | |
| ZA98576B (en) | Gemcitabine derivatives | |
| HU9603105D0 (en) | Adenosine derivatives | |
| EP1061912A4 (en) | PHENANTHROFURANDERIVATE | |
| IL139276A0 (en) | Cyclohexenondioxthio chromanoyl derivatives | |
| HK1042478A1 (zh) | 2-氧代-2h-喹啉衍生物 | |
| GB9826153D0 (en) | Hydrazine derivatives | |
| AU2002323990A1 (en) | Adenosine derivatives | |
| IL137605A0 (en) | Nucleosides | |
| GB9813919D0 (en) | Hydrazine derivatives | |
| GB9816279D0 (en) | Arylthiazolidinedione derivatives | |
| SI1051395T1 (sl) | N-hidroksiformamidni derivati | |
| EG23813A (en) | Carbohydrate derivatives | |
| PL344600A1 (en) | Adenosine a3 | |
| PL342404A1 (en) | Nucleosides |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FF | Patent granted | ||
| KB | Patent renewed |